AMGEN, INC. for AMGEN INC
What was lobbied
5 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Issues related to drug pricing Issues related to cardiovascular disease awareness and treatment Issues related to FDA Issues related to patient affordability issues, including copay cards, copay accumulators, copay maximizers, National Benefit Payment Parameters Issues related to biosimilars reimbursement Issues related to Supply Chain Issues related to 340B Issues related to pharmacy benefit managers Issues related to biosimilars regulatory standards Issues related to bone disease awareness and treatment Issues related to Public law 117-1769 Inflation Reduction Act HR 1492 Ensuring Pathways to Innovative Cures Act HR 1672 Maintaining Investments in New Innovation Act HR 1 One Big Beautiful Bill Act (An Act to provide for reconciliation pursuant to title II of H. Con. Res. 14) S 1954 Biosimilar Red Tape Elimination Act S.3345 PBM Price Transparency and Accountability Act H.R. 6166 Lowering Drug Costs for American Families Act S.3019 No Big Blockbuster Bailouts Act HR 4317 PBM Reform Act S 3510 Biosimilar Inspection Modernization Act PL 119-75 Consolidated Appropriations Act of 2026 HR 4299 Protecting Patient Access to Cancer and Complex Therapies Act H.R.7837 Most Favored Patient Act of 2026 S 3788 Clear Labels Act HR 5256 340B Access Act H.R.5526 Biosimilar Red Tape Elimination Act HR 7391 Community Health Center Drug Pricing Protection Act
| Lobbyist | Covered position, as disclosed |
|---|---|
| L NICOLE CURRIE | — |
| RUTH HOFFMAN | — |
| JESSE KERNS | — |
| JORDAN LYNN LAYSON | — |
| KIMBERLY LOVE | — |
| MATTHEW MCMURRAY | — |
| HOWARD MOON | — |
| WILLIAM O'BRIEN | — |
| CHAD PETTIT | — |
| GREGORY PORTNER | — |
| HELEN RHEE | — |
| CHASE THOMAS | — |
Medicare/Medicaid MMM
Issues related to drug pricing Issues related to cardiovascular disease awareness and treatment Issues related to reimbursement for biologics/biosimilars Issues related to PBM reform Issues related to bone disease awareness and treatment HR 1 One Big Beautiful Bill Act (An Act to provide for reconciliation pursuant to title II of H. Con. Res. 14) S.3345, PBM Price Transparency and Accountability Act HR 6166, Lowering Drug Costs for American Families Act S 3019 - No Big Blockbuster Bailouts Act S 3349 PBM Disclosure Act HR 4317 PBM Reform Act Issues related to Public law 117-1769 Inflation Reduction Act HR 1492 Ensuring Pathways to Innovative Cures Act (EPIC) HR 1672 Maintaining Investments in New Innovation Act (MINI) HR 4299 Protecting Patient Access to Cancer and Complex Therapies Act H.R.7837 Most Favored Patient Act of 2026 PL 119-75 Consolidated Appropriations Act of 2026
| Lobbyist | Covered position, as disclosed |
|---|---|
| L NICOLE CURRIE | — |
| RUTH HOFFMAN | — |
| JESSE KERNS | — |
| JORDAN LYNN LAYSON | — |
| KIMBERLY LOVE | — |
| MATTHEW MCMURRAY | — |
| HOWARD MOON | — |
| WILLIAM O'BRIEN | — |
| CHAD PETTIT | — |
| GREGORY PORTNER | — |
| HELEN RHEE | — |
| CHASE THOMAS | — |
Taxation/Internal Revenue Code TAX
Issues related to corporate and international tax Public Law 115-97, Tax Cuts and Jobs Act Public Law 119-21, One Big Beautiful Bill Act (An Act to provide for reconciliation pursuant to title II of H. Con. Res. 14) Issues related to Puerto Rico Issues related to OECD negotiations on the taxation of global income
| Lobbyist | Covered position, as disclosed |
|---|---|
| L NICOLE CURRIE | — |
| JORDAN LYNN LAYSON | — |
| WILLIAM O'BRIEN | — |
| GREGORY PORTNER | — |
| HELEN RHEE | — |
| CHASE THOMAS | — |
Copyright/Patent/Trademark CPT
Federal Trade Commission related issues Issues related to the Patent Act, no specific bill Issues related to March-In/Bayh Dole, WTO/TRIPS Issues related to patent thickets Issues related to obviousness/ double patenting Issues related to FDA/PTO coordination Issues related to skinny labeling S.1041 A bill to amend title 35, United States Code, to address the infringement of patents that claim biological products, and for other purposes S.1040 -A bill to amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes S 708/ HR 1574 -- Realizing Engineering, Science and Technology Opportunities by Restoring Exclusive Patent Rights Act of 2025 (RESTORE) S.1553/HR3160-- Promoting and Respecting Economically Viable American Innovation Act (PREVAIL) S. 1546/ HR 3152-- Patent Eligibility Restoration Act of 2025 (PERA) S 2276 / HR 3269 Eliminating Thickets to Increase Competition Act (ETHIC Act) S. 43/HR 6485 Skinny Labels Big Savings Act S.2658 Medication Affordability and Patent Integrity Act S. 3452/HR 6624 Biological Intellectual Property Protection Act of 2025
| Lobbyist | Covered position, as disclosed |
|---|---|
| WILLIAM O'BRIEN | — |
| HELEN RHEE | — |
Tariff (miscellaneous tariff bills) TAR
Issues related to tariffs Issues related to trade agreements S. 3452/HR 6624 Biological Intellectual Property Protection Act of 2025
| Lobbyist | Covered position, as disclosed |
|---|---|
| L NICOLE CURRIE | — |
| JESSE KERNS | — |
| JORDAN LYNN LAYSON | — |
| KIMBERLY LOVE | — |
| MATTHEW MCMURRAY | — |
| HOWARD MOON | — |
| WILLIAM O'BRIEN | — |
| GREGORY PORTNER | — |
| HELEN RHEE | — |
| CHASE THOMAS | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.